Business
Aquestive Therapeutics Announces Expert Allergy Scientific Advisory Board
WARREN, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients'
About this update from Aquestive Therapeutics, Inc.
[{"type":"text","content":"WARREN, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today the establishment of a Scientific Advisory Board comprised of eight allergy experts. “We are very pleased to welcome these leading experts to our Scientific Advisory Board,” said Dan Barber, Chief Executive Officer of Aquestive. “The accomplished individuals on our board have made significant contributions and breakthroughs in the Allergy and Immunology space, and together will bring a deep wealth of knowledge and expertise to Aquestive as we advance our AQST-109 platform and aim to make significant contributions to patients. With our planned pivotal and pediatric studies, and continued interactions with the FDA, there is no better time than now to compose an elite Scientific Advisory Board that can provide their expert insights and guidance to our program.” The Scientific Advisory Board includes eight allergy experts as follows: David Bernstein, MD, is Professor Emeritus of Medicine in the Division of Immunology and Allergy at the University of Cincinnati College of Medicine where he is co-director of the Allergy Fellowship training program. He is a former Principal Investigator of a training grant for 3 funding cycles through the National Institute of Allergy and Infectious Diseases (NIAID). Dr. Bernstein has authored or co-authored over 270 original publications. He has been engaged in the practice of Allergy and Clinical Immunology for the past 40 years. Major research interests of Dr. Bernstein include new therapies for asthma and allergic disorders, environmental causes of asthma, allergen immunotherapy and occupational asthma. Dr. Bernstein has received the Distinguished Clinician Award from the American Academy of Allergy Asthma and Immunology and this year he received the Distinguished Alumni Award from the University of Cincinnati College of Medicine. Carlos Camargo, MD, is a Professor of Emergency Medicine, Medicine, and Epidemiology at Harvard University, and the Conn Chair in Emergency Medicine at Massachusetts General Hospital. He has over 1,200 publications, with an H-index of 149. He founded and leads the Emergency Medicine Network (EMNet), an ...